INGRESS published a paper about cost of urinary tract infections in type 2 diabetes patients; 456,586 T2DM-patients were included from a regional German healthcare fund database. We calculated UTI-associated resource costs. We observed 48,337 UTI events. The direct mean resource-based costs were €315.90 per UTI event. Healthcare costs per patient year were €3,916 higher in
The Ingress-health team recently published the very first discrete-choice based preference analysis in patients with age-related wet macula degeneration. This technique had not been used so far in this disease, so this is the first worldwide publication in this respect. It is published in the high-impact ophthalmology journal “Ophthalmology”. The results of the analysis show
In our recently published work, we have utilized data from two large retrospective datasets: a German claims dataset and the UK General Practitioner (GP)-based Clinical Practice Research Datalink (CPRD) dataset (2010–2012). The study included 1,905 and 1,627 type 2 diabetes mellitus (T2DM) patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists from the UK and Germany, respectively.
Insights from a real-world setting, 456,586 T2DM German patients. In our recently published work we investigated urinary tract infection (UTI) incidence among Type 2 Diabetes mellitus (T2DM) patients in Germany. Moreover, we aimed to identify risk factors associated with UTI incidence/recurrence. A total of 456,586 T2DM- patients were identified. Overall, the UTI event rate was
Between January and October 2014, 647 patients with non-valvular AF were included by 57 practitioners and 486 AF patients could be interviewed. The results showed that when deciding about an anticoagulation treatment, AF patients prefer treatments that can be taken once daily, that do not require any bridging in case of surgeries, and do not
Validation of the Adherence Barriers Questionnaire (ABQ) – An Instrument for Identifying Potential Risk Factors Associated With Medication-Related Non-Adherence Summary: Medication-related non-adherence is a major challenge in the real-life treatment of patients. To meet this challenge successfully, adherence interventions with a tailored approach towards patient-specific adherence barriers are needed. Therefore, a reliable and practicable questionnaire
Real-life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients. Authors: Thomas Wilke, Antje Groth, Andreas Fuchs, Lisa Seitz, Joachim Kienhöfer, Rainer Lundershausen and Ulf Maywald Objectives: The aim of this claims-based data analysis was to describe the care of German T2DM patients and to determine which
Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus Authors: Thomas Wilke, Sabrina Müller, Antje Groth, Andreas Fuchs, Lisa Seitz, Joachim Kienhöfer, Ulf Maywald, Rainer Lundershausen and Martin Wehling Journal: Cardiovascular Diabetology For more information on this paper please contact